Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
cell therapy
endothelial cells
hepatic stellate cells
hepatocytes
hypoimmunogenic iPSC
regenerative medicine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Jul 2023
22 Jul 2023
Historique:
received:
07
06
2023
revised:
13
07
2023
accepted:
19
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Induced pluripotent stem cells (iPSC) have huge potential as cell therapy for various diseases, given their potential for unlimited self-renewal and capability to differentiate into a wide range of cell types. Although autologous iPSCs represents the ideal source for patient-tailored regenerative medicine, the high costs of the extensive and time-consuming production process and the impracticability for treating acute conditions hinder their use for broad applications. An allogeneic iPSC-based strategy may overcome these issues, but it carries the risk of triggering an immune response. So far, several approaches based on genome-editing techniques to silence human leukocyte antigen class I (HLA-I) or II (HLA-II) expression have been explored to overcome the immune rejection of allogeneic iPSCs. In this study, we employed the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9) system to delete the β2-Microglobulin (
Identifiants
pubmed: 37511568
pii: ijms241411810
doi: 10.3390/ijms241411810
pmc: PMC10380710
pii:
doi:
Substances chimiques
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Telethon Foundation
ID : GGP20073
Organisme : Roche (Italy)
ID : NA
Références
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31527312
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Stem Cell Res Ther. 2018 Mar 9;9(1):58
pubmed: 29523187
Front Bioeng Biotechnol. 2022 Nov 25;10:942750
pubmed: 36507264
Stem Cell Res. 2021 Oct 18;57:102580
pubmed: 34688128
Nucleic Acids Res. 2018 Jul 2;46(W1):W242-W245
pubmed: 29762716
Front Immunol. 2021 Apr 02;12:662360
pubmed: 33897711
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10441-10446
pubmed: 31040209
Ann Transl Med. 2020 Apr;8(8):566
pubmed: 32775367
iScience. 2020 Jun 26;23(6):101162
pubmed: 32502965
Stem Cells Transl Med. 2015 Oct;4(10):1234-45
pubmed: 26285657
Cells. 2020 Feb 12;9(2):
pubmed: 32059501
Nucleic Acids Res. 2021 Jul 2;49(W1):W446-W451
pubmed: 33893808
Nature. 2017 Jun 15;546(7658):370-375
pubmed: 28489815
Cell Mol Life Sci. 2018 Apr;75(8):1307-1324
pubmed: 29181772
J Immunol Res. 2022 May 26;2022:9710376
pubmed: 35664353
Cells. 2020 Jan 27;9(2):
pubmed: 32012725
Stem Cells. 2022 Sep 26;40(9):791-801
pubmed: 35671338
PLoS One. 2017 Mar 16;12(3):e0174077
pubmed: 28301575
Dis Model Mech. 2020 Jan 17;13(1):
pubmed: 31953356
Front Immunol. 2020 Jun 23;11:1295
pubmed: 32714324
Nat Biomed Eng. 2021 May;5(5):429-440
pubmed: 34002062
Nat Biotechnol. 2019 Mar;37(3):252-258
pubmed: 30778232
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33416832
Sci Rep. 2019 Feb 14;9(1):2072
pubmed: 30765795
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7
pubmed: 30853558
Sci Rep. 2019 May 29;9(1):8001
pubmed: 31142801